MedTrace Logo

Adiponectin in Obese Women With T2DN and Effects by RAS Blocker

NCT00561704 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2007-11-21

No results posted yet for this study

Summary

Insulin resistance typically characterizes type 2 diabetes (T2DM) and prediabetic states and is the prominent feature of the metabolic syndrome.Adiponectin plays an important part in glucose metabolism,insulin resistance, the deterioration of renal function.we hypothesize there is a difference serum adiponectin levels between obese and non-obese women with type 2 diabetic nephropathy. Furthermore, these two groups would respond difference to the RAs blocker(Losartan).

Conditions

  • Obese
  • Type 2 Diabetes
  • Diabetic Nephropathy
  • Glucose Metabolism
  • Angiotensin II Type 1 Receptor Blockers

Interventions

DRUG

losartan

losartan, 100mg daily,

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • hui min Jin, MD · shanghai No 3 people's hospital

Study Design

Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Completion
2007-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00561704 on ClinicalTrials.gov